{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:41:49Z","timestamp":1793112109873,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study was conducted as a retrospective, exploratory analysis to assess early anatomical and functional effects of intravitreal aflibercept 8\u00a0mg in neovascular age-related macular degeneration (nAMD) in a small cohort of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study was conducted at the Jules Gonin Eye Hospital in Lausanne, Switzerland, and included treatment-na\u00efve patients with nAMD. Patients received a minimum of two intravitreal injections (IVT) of aflibercept 8\u00a0mg over a 3-month period. Key outcomes assessed were changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), mean retinal thickness (RT), total fluid (TF) volume which was calculated as the sum of intraretinal fluid (IRF), subretinal fluid (SRF) and pigment epithelial detachment (PED) volumes. These parameters were evaluated at baseline, month 1, and month 3 using the RetinAI Discovery\n                      <jats:sup>\u00ae<\/jats:sup>\n                      platform, an artificial intelligence-based analysis system.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>10 eyes of 10 patients were enrolled. Mean age was 77.7\u2009\u00b1\u200912.5 years. Comparative analysis between baseline, month 1, and month 3 revealed statistically significant reduction in CST, RT and TF volume, indicating a positive early response to treatment. One adverse event of intraocular inflammation (IOI) occurred in one patient (10%) after the second IVT injection. Treatment was subsequently interrupted, and IOI resolved with topical corticosteroids therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intravitreal aflibercept 8\u00a0mg demonstrated early anatomical and functional improvements in nAMD treatment-na\u00efve patients after the first 3-months. The use of the AI-based analysis allowed for detailed and automated assessment of retinal changes, providing valuable insights into early treatment effects. Given the retrospective design and small cohort, further studies are warranted to assess long-term outcomes and the potential predictive value of early changes on long-term visual prognosis and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00665-6","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T14:13:47Z","timestamp":1744121627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Early real-world outcomes of intravitreal aflibercept 8\u00a0mg in treatment-Na\u00efve neovascular AMD: AI-assisted fluid volume analysis"],"prefix":"10.1186","volume":"11","author":[{"given":"Jennifer","family":"Cattaneo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva C.","family":"De Oliveira Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Montesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vermeirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara M.","family":"Eandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"665_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/OPTH.S231913","volume":"16","author":"CS Tan","year":"2022","unstructured":"Tan CS, Ngo WK, Chay IW, Ting DS, Sadda SR. Neovascular Age-Related macular degeneration (nAMD): A review of emerging treatment options. Clin Ophthalmol. 2022;16:917\u201333.","journal-title":"Clin Ophthalmol"},{"key":"665_CR2","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.ophtha.2009.06.048","volume":"116","author":"NM Bressler","year":"2009","unstructured":"Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology. 2009;116:S15\u201323.","journal-title":"Ophthalmology"},{"key":"665_CR3","first-page":"CD012208","volume":"5","author":"E Li","year":"2020","unstructured":"Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020;5:CD012208.","journal-title":"Cochrane Database Syst Rev"},{"key":"665_CR4","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.3390\/ijms25084433","volume":"25","author":"S Fragiotta","year":"2024","unstructured":"Fragiotta S, Bassis L, Abdolrahimzadeh B, Marino A, Sepe M, Abdolrahimzadeh S. Exploring current molecular targets in the treatment of neovascular Age-Related macular degeneration toward the perspective of Long-Term agents. Int J Mol Sci. 2024;25:4433.","journal-title":"Int J Mol Sci"},{"key":"665_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, Double-Masked trials of Brolucizumab for neovascular Age-Related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"665_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"665_CR7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, et al. Effect of High-Dose intravitreal Aflibercept, 8\u00a0mg, in patients with neovascular Age-Related macular degeneration: the phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol. 2023;141:834\u201342.","journal-title":"JAMA Ophthalmol"},{"key":"665_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik J-F, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal Aflibercept 8\u00a0mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352.","journal-title":"Lancet"},{"key":"665_CR9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, et al. Intravitreal Aflibercept 8\u00a0mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403:1153\u201363.","journal-title":"Lancet"},{"key":"665_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/bjo-2022-322297","volume":"108","author":"R Martin-Pinardel","year":"2024","unstructured":"Martin-Pinardel R, Izquierdo-Serra J, Zanet SD, Parrado-Carrillo A, Garay-Aramburu G, Puzo M, et al. Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration National database. Br J Ophthalmol. 2024;108:253\u201362.","journal-title":"Br J Ophthalmol"},{"key":"665_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/bjophthalmol-2021-319211","volume":"107","author":"FG Holz","year":"2023","unstructured":"Holz FG, Abreu-Gonzalez R, Bandello F, Duval R, O\u2019Toole L, Pauleikhoff D, et al. Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study. Br J Ophthalmol. 2023;107:96\u2013101.","journal-title":"Br J Ophthalmol"},{"key":"665_CR12","doi-asserted-by":"crossref","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509\u201316.","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"665_CR13","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","volume":"35","author":"U Chakravarthy","year":"2021","unstructured":"Chakravarthy U, Havilio M, Syntosi A, Pillai N, Wilkes E, Benyamini G, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye (Lond). 2021;35:2983\u201390.","journal-title":"Eye (Lond)"},{"key":"665_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.survophthal.2023.10.013","volume":"69","author":"A Feo","year":"2024","unstructured":"Feo A, Stradiotto E, Sacconi R, Menean M, Querques G, Romano MR. Subretinal hyperreflective material in retinal and chorioretinal disorders: A comprehensive review. Surv Ophthalmol. 2024;69:362\u201377.","journal-title":"Surv Ophthalmol"},{"key":"665_CR15","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.ophtha.2011.03.020","volume":"118","author":"JS Heier","year":"2011","unstructured":"Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology. 2011;118:1098\u2013106.","journal-title":"Ophthalmology"},{"key":"665_CR16","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","volume":"121","author":"AC Ho","year":"2014","unstructured":"Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, et al. Twenty-four-month efficacy and safety of 0.5\u00a0mg or 2.0\u00a0mg Ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121:2181\u201392.","journal-title":"Ophthalmology"},{"key":"665_CR17","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1038\/s41433-024-03312-w","volume":"38","author":"J-F Korobelnik","year":"2024","unstructured":"Korobelnik J-F, Lanzetta P, Wykoff CC, Wong TY, Zhang X, Morgan-Warren P, et al. Sustained disease control with Aflibercept 8\u00a0mg: a new benchmark in the management of retinal neovascular diseases. Eye (Lond). 2024;38:3218\u201321.","journal-title":"Eye (Lond)"},{"key":"665_CR18","volume-title":"Intraocular inflammation (IOI) associated with faricimab therapy","author":"A Montesel","year":"2025","unstructured":"Montesel A, Sen S, Preston E, Patel PJ, Huemer J, Hamilton RD, et al. Intraocular inflammation (IOI) associated with faricimab therapy. Retina: One-year Real World Outcomes; 2025."},{"key":"665_CR19","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jamaophthalmol.2024.3828","volume":"142","author":"M Cozzi","year":"2024","unstructured":"Cozzi M, Ziegler A, Fasler K, Muth DR, Blaser F, Zweifel SA. Sterile intraocular inflammation associated with faricimab. JAMA Ophthalmol. 2024;142:1028\u201336.","journal-title":"JAMA Ophthalmol"},{"key":"665_CR20","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s12886-024-03788-w","volume":"24","author":"L Hoffmann","year":"2024","unstructured":"Hoffmann L, Michels S, Eandi C, Karam MA, Figueiredo EC, de Hatz O. Aflibercept high-dose (8\u00a0mg) related intraocular inflammation (IOI) - a case series. BMC Ophthalmol. 2024;24:520.","journal-title":"BMC Ophthalmol"},{"key":"665_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10384-024-01107-w","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Numaga S, Mimura K, Asatori Y, Akiyama H. Retinal vasculitis after intravitreal Aflibercept 8\u00a0mg for neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68:531\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"665_CR22","doi-asserted-by":"publisher","first-page":"1196033","DOI":"10.3389\/fimmu.2023.1196033","volume":"14","author":"M Medrano-Bosch","year":"2023","unstructured":"Medrano-Bosch M, Sim\u00f3n-Codina B, Jim\u00e9nez W, Edelman ER, Melgar-Lesmes P. Monocyte-endothelial cell interactions in vascular and tissue remodeling. Front Immunol. 2023;14:1196033.","journal-title":"Front Immunol"},{"key":"665_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","volume":"6","author":"HX Chen","year":"2009","unstructured":"Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6:465\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"665_CR24","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/bjo-2022-323014","volume":"108","author":"V Mares","year":"2024","unstructured":"Mares V, Schmidt-Erfurth UM, Leingang O, Fuchs P, Nehemy MB, Bogunovic H, et al. Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine. Br J Ophthalmol. 2024;108:971\u20137.","journal-title":"Br J Ophthalmol"},{"key":"665_CR25","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ophtha.2020.03.010","volume":"127","author":"U Schmidt-Erfurth","year":"2020","unstructured":"Schmidt-Erfurth U, Vogl W-D, Jampol LM, Bogunovi\u0107 H. Application of automated quantification of fluid volumes to Anti\u2013VEGF therapy of neovascular Age-Related macular degeneration. Ophthalmology. 2020;127:1211\u20139.","journal-title":"Ophthalmology"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00665-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00665-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00665-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T14:13:49Z","timestamp":1744121629000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00665-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["665"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00665-6","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"22 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved locally by the ethics committee of Canton Vaud (Switzerland) CERVD: 2017\u2009\u2212\u200900493. Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.M.: educational grants, speaker fees, travel fees from Roche, Bayer. S.V.: travel fees from Bayer. Other authors: no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}